Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FCSC
CUSIPN/A
Phone484-713-6000
Debt
Debt-to-Equity RatioN/A
Current Ratio6.75
Quick Ratio6.75
Price-To-Earnings
Trailing P/E Ratio-0.30
Forward P/E Ratio-1.37
P/E GrowthN/A
Sales & Book Value
Annual Sales$350,000.00
Price / Sales40.50
Cash FlowN/A
Price / CashN/A
Book Value$1.74 per share
Price / Book1.44
Profitability
EPS (Most Recent Fiscal Year)($8.25)
Net Income$-16,240,000.00
Net MarginsN/A
Return on Equity-886.87%
Return on Assets-115.44%
Miscellaneous
Employees20
Outstanding Shares5,670,000
Market Cap$14.18
Fibrocell Science (NASDAQ:FCSC) Frequently Asked Questions
What is Fibrocell Science's stock symbol?
Fibrocell Science trades on the NASDAQ under the ticker symbol "FCSC."
When did Fibrocell Science's stock split? How did Fibrocell Science's stock split work?
Fibrocell Science's stock reverse split on the morning of Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 24th 2018. An investor that had 100 shares of Fibrocell Science stock prior to the reverse split would have 20 shares after the split.
How were Fibrocell Science's earnings last quarter?
Fibrocell Science Inc (NASDAQ:FCSC) announced its quarterly earnings data on Thursday, May, 10th. The company reported ($0.55) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.85) by $0.30. View Fibrocell Science's Earnings History.
When is Fibrocell Science's next earnings date?
What price target have analysts set for FCSC?
3 Wall Street analysts have issued 1-year price objectives for Fibrocell Science's stock. Their predictions range from $22.00 to $35.00. On average, they expect Fibrocell Science's share price to reach $28.50 in the next twelve months. This suggests a possible upside of 1,040.0% from the stock's current price. View Analyst Ratings for Fibrocell Science.
What is the consensus analysts' recommendation for Fibrocell Science?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fibrocell Science in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Fibrocell Science's key competitors?
Some companies that are related to Fibrocell Science include Celsion (CLSN), IntelGenx Technologies (IGXT), Zosano Pharma (ZSAN), vTv Therapeutics (VTVT), Addex Pharmaceuticals (ADDXF), Heat Biologics (HTBX), Imprimis Pharmaceuticals (IMMY), Humanigen (HGEN), Moleculin Biotech (MBRX), AzurRx BioPharma (AZRX), Evoke Pharma (EVOK), Acerus Pharmaceuticals (TRLPF), Capricor Therapeutics (CAPR), Avenue Therapeutics (ATXI) and Xenetic Biosciences (XBIO).
Who are Fibrocell Science's key executives?
Fibrocell Science's management team includes the folowing people:
- Mr. John Michael Maslowski, Pres, CEO, PFO, Principal Accounting Officer & Director (Age 43)
- Mr. Robert G. Partridge, VP of Global Marketing, Communications and Investor Relations
- Ms. Michele Mchugh-Mazzatta, VP of Sales
- Dr. Pierre Compte, Managing Director of Switzerland
- Dr. Alfred T. Lane, Chief Medical Advisor & Member of Scientific Advisory Board
Has Fibrocell Science been receiving favorable news coverage?
Headlines about FCSC stock have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fibrocell Science earned a coverage optimism score of 0.11 on Accern's scale. They also assigned news stories about the company an impact score of 45.17 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Fibrocell Science's major shareholders?
Fibrocell Science's stock is owned by a variety of of retail and institutional investors. Top institutional investors include CVI INVESTMENTS, INC. (8.80%), ANSON FUNDS MANAGEMENT LP (8.80%) and SABBY MANAGEMENT, LLC (8.81%). Company insiders that own Fibrocell Science stock include David Pernock and Randal J Kirk. View Institutional Ownership Trends for Fibrocell Science.
How do I buy shares of Fibrocell Science?
Shares of FCSC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fibrocell Science's stock price today?
One share of FCSC stock can currently be purchased for approximately $2.50.
How big of a company is Fibrocell Science?
Fibrocell Science has a market capitalization of $14.18 million and generates $350,000.00 in revenue each year. The company earns $-16,240,000.00 in net income (profit) each year or ($8.25) on an earnings per share basis. Fibrocell Science employs 20 workers across the globe.
How can I contact Fibrocell Science?
Fibrocell Science's mailing address is 405 EAGLEVIEW BOULEVARD, EXTON PA, 19341. The company can be reached via phone at 484-713-6000 or via email at [email protected]
MarketBeat Community Rating for Fibrocell Science (NASDAQ FCSC)
MarketBeat's community ratings are surveys of what our community members think about Fibrocell Science and other stocks. Vote "Outperform" if you believe FCSC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FCSC will underperform the S&P 500 over the long term. You may vote once every thirty days.
